

RENAL CANCER BIOMARKERS

SUMMARY

The National Cancer Institute's Laboratory of Proteomics and Analytical Technologies is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize diagnostic, therapeutic and prognostic cancer biomarkers from clinical specimens.

REFERENCE NUMBER

E-317-2008

PRODUCT TYPE

- Diagnostics

COLLABORATION OPPORTUNITY

This invention is available for licensing and co-development.

CONTACT

John D. Hewes
NCI - National Cancer Institute
240-276-5515

John.Hewes@nih.gov

DESCRIPTION OF TECHNOLOGY

Renal Cell Carcinoma is the most common type of kidney cancer and its incidence is rising steadily. There is an acute need for cancer biomarkers that can be detected from clinically relevant samples and used for early diagnosis, treatment, follow-up, and prognosis of the disease.

This invention describes the identification of potential renal cancer biomarkers that could be utilized in the development of renal cancer diagnostics, personalized treatment, follow up and prognostics. The invention identifies cancer protein biomarkers from clinically relevant samples including peripheral blood and fresh frozen tissues.

Further R&D Needed:

- Fresh frozen tissues and peripheral blood specimens that are easily obtained could lead to clinical tests amenable to therapeutic, prognostic, and even early screening tests for renal cell carcinoma and other malignancies.
- Develop a proteomic platform resulting in discovery of biomarkers for other cancers
- Conduct clinical tests for diagnosis, therapeutic-guidance, follow-up, prognosis, tumor staging and cancer screening.

POTENTIAL COMMERCIAL APPLICATIONS

Renal cell carcinoma diagnostics, therapeutics, and prognostics

COMPETITIVE ADVANTAGES

- Can be detected from peripheral blood and fresh frozen tissue specimens.

DEVELOPMENT STAGE

- Pre-clinical (in vivo)

PATENT STATUS

- U.S. Issued: US 9,140,687, US 8,790,869

THERAPEUTIC AREA

- Cancer/Neoplasm